Education
Anthos Therapeutics is committed to advancing the science of Factor XI inhibition through educational activities with many of the leading organizations in the field.
The information provided on this page is for educational purposes only. It is not intended to be, and should not be, understood to provide medical advice.
Patient Advocacy
Healthcare Professionals
These sites are provided as educational resources for healthcare professionals and may include products or uses that have not been approved by the US Food and Drug Administration or other regulatory agencies. Factor XI / XIa inhibitors are investigational agents and are not approved for any indication in any country.
2024
Accreditation:
Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.
Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio.
2023
Credit: 0.5 AMA PRA Category 1 Credit™, 0.5 ANCC contact hours, 0.5 ACPE contact hours, and ABIM MOC contact hours
Moderator:
Marc S. Sabatine, MD, MPH
Chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, the Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women’s Hospital (BWH), and a Professor of Medicine at Harvard Medical School (HMS).
Panelists:
Christian T. Ruff, MD, MPH
Director, General Cardiology, Brigham and Women’s Hospital; Senior Investigator, TIMI Study Group; Associate Member, Broad Institute of MIT and Harvard; Associate Professor of Medicine, Harvard Medical School
Jeffrey I. Weitz, MD, FRCPC, FRSC, FACP, FCCP
Professor of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Executive Director, Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
Evaluating Evolving Approaches to Treating Thrombosis in Cancer: From Concept to Clinic
Faculty:
Jean M. Connors, MD
Medical Director, Hemostatic Antithrombotic Stewardship
Medical Director, Anticoagulation Management Services (Hematology Division), Brigham and Women’s Hospital/Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts, United States
Alok A. Khorana, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Sondra and Stephen Hardis Chair in Oncology Research; Vice Chair, Clinical Services; Director, GI Malignancies Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
Jeffrey I. Weitz, MD, FRCPC, FRSC, FACP, FCCP
Professor of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Executive Director, Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
The information provided on this page is for educational purposes only. It is not intended to be, and should not be, understood to provide medical advice. Factor XI inhibitors, including abelacimab, are investigational agents and are not approved for any indication in any country.